Table 3.
Treatment details, toxicities, and outcome of patients.
| PD-1/PDL-1 inhibitor(course) | Targeted agent | RT site | RT dose(Gy) | RT technique | Prior treatment | Toxicity | Tumor response | Status | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sintilimab(4) | Sorafenib | Liver | 40 | SBRT | No | Grade 2 decreased appetite | PD | Alive |
| 2 | Tislelizumab(7) | Sorafenib, regorafenib | Liver | 60 | Hypofractionated RT | Hepatectomy, radiofrequency ablation | Grade 1 rash, Grade 2 hypertension | SD | Alive |
| 3 | Sintilimab, camrelizumab(14) | Regorafenib, apatinib | Liver | 54 | Hypofractionated RT | Radiofrequency ablation,TACE, sorafenib | Grade 2 rash | PR | Alive |
| 4 | Camrelizumab(6) | Lenvatinib | Liver | 45 | Conventional RT | TACE, lenvatinib | Grade 2 diarrhea, decreased appetite, fatigue | PR | Alive |
| 5 | Sintilimab(10) | Sorafenib, regorafenib | Liver | 45 | Conventional RT | TACE, sorafenib | Grade 2 nausea | SD | Alive |
| 6 | Camrelizumab(3) | Apatinib, regorafenib | Liver | 54 | Hypofractionated RT | Radiofrequency ablation,TACE | Grade 3 rash; Grade 2 infusion-related reaction; Grade 2 pruritus; Grade 2 blood bilirubin/aspartate aminotransferase/alanine transaminase increase | PR | Alive |
| 7 | Pembrolizumab(6) | Apatinib | Liver | 50 | SBRT | Apatinib | Grade 1 diarrhea | PD | Death |
| 8 | Nivolumab(7) | Sorafenib | Liver | 45 | SBRT | No | Grade 2 alanine transaminase increase; Grade 3 aspartate aminotransferase increase | PR | Alive |
| 9 | Atezolizumab(1) | Bevacizumab | Bone | 36 | Hypofractionated RT | No | – | – | Alive |
| 10 | Tislelizumab(3) | Lenvatinib | Soft tissue of the lumbar spine | 36 | Hypofractionated RT | TACE | Grade 2 dental ulcer,diarrhea,decreased appetite,weight decrease | PR | Alive |
| 11 | Toripalimab(4) | Lenvatinib, regorafenib | Bone | 40 | SBRT | No | Grade 1 fatigue; Grade 2 aspartate aminotransferase increase; Grade 3 alanine transaminase increase | SD | Death |
| 12 | Camrelizumab(9) | Sorafenib, lenvatinib | Bone | 40 | Conventional RT | Hepatectomy,TACE, sorafenib | Grade 1 fatigue | SD | Death |
| 13 | Camrelizumab(4) | Lenvatinib | Bone | 35 | SBRT | Hepatectomy, radiofrequency ablation,TACE, sorafenib | Grade 2 rash, pruritus, nausea | SD | Death |
| 14 | Tislelizumab, atezolizumab(10) | Lenvatinib, regorafenib | Brain | 42 | SBRT | Hepatectomy | Grade 2 diarrhea | SD | Alive |
| 15 | Camrelizumab(10) | Sorafenib, regorafenib | Bone | 30 | Hypofractionated RT | Hepatectomy,TACE | Grade 2 dental ulcer | SD | Alive |
| 16 | Sintilimab(8) | Regorafenib | Inferior vena cava tumor thrombus | 55 | Hypofractionated RT | Hepatectomy, radiofrequency ablation,TACE, sorafenib | Grade 4 gastrointestinal hemorrhage | PR | Alive |
RT, radiotherapy; SBRT, stereotactic body radiotherapy; TACE, trans-arterial chemo-embolization; PR, partial response; SD, stable disease; PD, progressive disease.